Viridian Therapeutics (VRDN) announced the appointment of Jeff Ajer to its Board of Directors. Ajer most recently served as the Executive Vice President and Chief Commercial Officer at BioMarin Pharmaceutical (BMRN)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics Enters New $300M Sale Agreement
- Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges
- Viridian Therapeutics: Promising Pipeline and Strategic Progress Support Buy Rating
- Viridian Therapeutics: Promising Market Position and Growth Prospects Justify Buy Rating
- Viridian Therapeutics Reports Strong Progress and Financials